Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.57 |
| ▸ | CTSL | P07711 | 15/20 | 0.57 |
| ▸ | CTSS | P25774 | 11/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSV | O60911 | 2/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843731 | 0.94 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4317277 | 0.89 | CTSK (0.69) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4317293 | 0.89 | CTSK (0.69) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL13784231 | 0.88 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL13784264 | 0.83 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4312486 | 0.82 | CTSK (0.66) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4312489 | 0.82 | CTSK (0.66) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL13784234 | 0.81 | CTSK (0.66) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL6257545 | 0.80 | CTSK (0.53) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4316058 | 0.79 | CTSK (0.64) | CTSKCTSLCTSSCTSBCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1307203-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1307203-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001070232-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CTSK 1/4885CTSL 2/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.